Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

Neogenix Oncology is pleased to announce that it will be granted a European Patent relating to its NEO-301 antibody, to take effect beginning September 23, 2011.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

U.S. biopharmaceutical companies to benefit from Almac's European Product Launch workshop

Almac is hosting its inaugural European Product Launch workshop in Boston, MA on 17th May 2011. Targeted specifically at the biopharmaceutical sector, the workshop provides consultative advice and services to US companies to successfully launch drug products onto the European market.

11 May 2011

Women with invasive breast cancer can benefit from new genomic test

A new genomic test combining multiple signatures - a patient's estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity - shows promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer, according to research led by The University of Texas MD Anderson Cancer Center.

11 May 2011

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.

11 May 2011

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma, a company dedicated to specialty and orphan pharma products in oncology and supportive care, today announced that it has entered into an exclusive licensing agreement with Sosei Co. Ltd. for commercialization rights in Japan for Loramyc muco-adhesive buccal tablet.

11 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

Second subject enrolled in human embryonic stem cell therapy trial for subacute thoracic spinal cord injury

Researchers at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine and The Rehabilitation Institute of Chicago (RIC) recently enrolled their first subject in a national clinical research trial of a human embryonic stem cell-based therapy for participants with a subacute thoracic spinal cord injury.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

Telemis releases new software for medical image-management system

Telemis, the specialist in medical imaging solutions, has released new software for its medical image-management system, which provides a full-featured dual-modality PET/CT viewer on any PC across any hospital using Telemis software.

10 May 2011

Elekta to integrate cancer workflow and patient management tools into IBA's Proteus TK2 center

Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2, a turnkey proton therapy center from Belgium-based Ion Beam Applications.

From Elekta 10 May 2011

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments.

10 May 2011

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

10 May 2011

EpiCept first quarter net loss decreases to $2.5 million

EpiCept Corporation today announced operating and financial results for the three months ended March 31, 2011, and provided an update with respect to the Company's key business initiatives.

10 May 2011

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.

10 May 2011

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

UCSF scientists receive CIRM grants to advance degenerative muscle disease research

Three UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their investigations of treatment strategies for degenerative muscle diseases, such as muscular dystrophy, and heart disease, and to determine why human embryonic stem cells are susceptible to forming tumors.

10 May 2011

USPTO grants patent to Rosetta's human hsa-miR-497 for use in diagnostic tests

Rosetta Genomics today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,943,745, which is related to human hsa-miR-497 and its variants and covers the composition of matter.

10 May 2011

Dravet Syndrome Foundation awards OPKO Health grant to develop potential therapeutic agents

OPKO Health, Inc. announced today that it has been awarded a grant from the Dravet Syndrome Foundation to support the Company's efforts to develop potential therapeutic agents to treat a rare genetic disorder, Dravet Syndrome, also called severe myoclonic epilepsy of infancy, a severe form of epilepsy that usually appears during the first year of life.

9 May 2011

Confusion surrounds Medicare proposals, budget plan debate

News outlets report on the fits and starts of the ongoing budget deficit talks, including how plans for Medicare's future are faring and how politics are heating up — both in Washington and in a special congressional election beyond the Beltway.

9 May 2011

Oncology News and Research

Further Reading

Neogenix Oncology to receive European Patent for NEO-301 antibody for treatment of pancreatic cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

U.S. biopharmaceutical companies to benefit from Almac's European Product Launch workshop

Women with invasive breast cancer can benefit from new genomic test

Genentech submits vemurafenib NDA for BRAF V600 mutation-positive metastatic melanoma

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Second subject enrolled in human embryonic stem cell therapy trial for subacute thoracic spinal cord injury

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Telemis releases new software for medical image-management system

Elekta to integrate cancer workflow and patient management tools into IBA's Proteus TK2 center

Bayer's regorafenib granted FDA Fast Track designation for treatment of GIST

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

EpiCept first quarter net loss decreases to $2.5 million

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

OncoGenex first quarter revenue decreases to $1.2 million

UCSF scientists receive CIRM grants to advance degenerative muscle disease research

USPTO grants patent to Rosetta's human hsa-miR-497 for use in diagnostic tests

Dravet Syndrome Foundation awards OPKO Health grant to develop potential therapeutic agents

Confusion surrounds Medicare proposals, budget plan debate

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News